Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics

What Is the Predicted Market Size and CAGR of the Neurotrophic Keratitis Treatment Market by the End of the 2029?
The neurotrophic keratitis treatment market size has grown exponentially in recent years. It will grow from $1.08 billion in 2024 to $1.47 billion in 2025 at a compound annual growth rate (CAGR) of 36.3%. The growth in the historic period can be attributed to increased diagnoses, increasing injury and surgical procedures, rising research and development, global healthcare infrastructure.

The neurotrophic keratitis treatment market size is expected to see exponential growth in the next few years. It will grow to " $4.99 billion in 2029 at a compound annual growth rate (CAGR) of 35.9%. The growth in the forecast period can be attributed to educational initiatives, increasing clinical trials, advanced therapies, regulatory approvals. Major trends in the forecast period include improved diagnostic tools, digital health solutions, neuroprotection strategies, advanced ocular surface imaging.

Get your free report sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12968&type=smp

Which Factors Are Contributing Most to the Expansion of the Neurotrophic Keratitis Treatment Market?
The growing prevalence of eye diseases is expected to propel the growth of the neurotrophic keratitis treatment market going forward. Eye diseases are a wide range of medical problems and disorders that affect the structure and function of the eyes. Neurotrophic keratitis can aid in the improvement of corneal sensation, the promotion of healing, the prevention of infection, and the relief of pain and suffering. For instance, in March 2022, according to the reports shared by Eye Care One, a US-based eyecare career development services platform, it was estimated that 35 million US people will suffer from dry eye disease (DED) in 2022 and the prevalence will rise yearly. For instance, in May 2024, according to the Centers for Disease Control and Prevention, a US-based federal agency under the Department of Health and Human Services, over 3.4 million Americans aged 40 years and older are blind or visually impaired, which is expected to double by 2030. Therefore, the growing prevalence of eye diseases is driving the growth of the neurotrophic keratitis treatment market.

Which Key Segments Are Included in the Neurotrophic Keratitis Treatment Market Analysis?
The neurotrophic keratitis treatmentmarket covered in this report is segmented –
1) By Treatment: Topical Antibiotics; Recombinant Human Nerve Growth Factor (rhNGF); Amniotic Membrane Transplantation; Keratoplasty; Other Treatments
2) By Route of Administration: Oral; Topical; Other Routes of Administration
3) By Application: Stage I; Stage II; Stage III
4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users

Subsegments:
1) By Topical Antibiotics: Broad-Spectrum Antibiotics; Narrow-Spectrum Antibiotics
2) By Recombinant Human Nerve Growth Factor (rhNGF): Cenegermin Ophthalmic Solution; Other rhNGF-Based Solutions
3) By Amniotic Membrane Transplantation: Cryopreserved Amniotic Membrane; Dehydrated Amniotic Membrane
4) By Keratoplasty: Penetrating Keratoplasty; Lamellar Keratoplasty
5) By Other Treatments: Tarsorrhaphy; Therapeutic Contact Lenses

Which Disruptive Trends Are Reshaping the Competitive Landscape of the Neurotrophic Keratitis Treatment Market?
Major companies operating in the neurotrophic keratitis treatment market are developing innovative drugs and getting them approved to uphold their market position. Drug development is vital in neurotrophic keratitis treatment as current treatments are limited and there is a need for more effective treatments to prevent the progression of the disease. For instance, in December 2022, BRIM Biotechnology Inc., a Taiwan-based clinical-stage company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for BRM424 for the treatment of neurotrophic keratitis (NK). It is a recombinant type of human nerve growth factor that stimulates the proliferation and differentiation of corneal limbal stem cells to regenerate and restore the cornea's health in patients with neurotrophic keratitis.

Who Are the Top Industry Players Driving the Neurotrophic Keratitis Treatment Market Growth?
Major companies operating in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Grand Pharma Co. Ltd., Walgreen Co., Pfizer Inc., Johnson and Johnson, Bayer AG, Novartis AG, Abbott Laboratories, Gilead Biosciences Inc., Merck and Co. Inc., Allergan Inc., Alcon Inc., Bausch Health Companies Inc., Bausch & Lomb Inc., CooperVision Inc., Rohto Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Zhejiang Conba Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc., Laboratoires Thea SAS, Leadiant Biosciences Inc., ReGenTree LLC, Contacare Opthalmic Private Limited, Neuroptika Inc., Surgitech Innovation Private Limited.

Get the detailed neurotrophic keratitis treatment market report today
https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report

Which Regional Markets Offer the Most Promising Growth Opportunities for the Neurotrophic Keratitis Treatment Market?
North America was the largest region in the neurotrophic keratitis treatment market in 2024. The regions covered in neurotrophic keratitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Contact Us:
The Business Research Company: Market Research Reports
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: [email protected]

Follow Us On:
LinkedIn: The Business Research Company | LinkedIn